Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
FITC Anti-Human CD8a (OKT8) Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| FC |
|---|---|
| Isotype | Mouse IgG2a |
| Concentration | 5 uL (0.125 ug)/test |
| Reactivity | Human |
| Formulation | 10 mM NaH2PO4, 150 mM NaCl, 0.09% NaN3, 0.1% gelatin, pH7.2 |
| Host | Mouse |
| Gene ID | 925 |
|---|---|
| Gene Name | CD8A |
| Alternative Name(s) | CD8 alpha, leu-2a |
| Format | FITC |
| Preparation | This monoclonal antibody was purified from tissue culture supernatant via affinity chromatography. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation. It is recommended to store the product undiluted at 4°C, and protected from prolonged exposure to light. Do not freeze. |
| Application Notes | This antibody preparation has been pre-titrated and quality-tested for flow cytometry using an appropriate cell type. The antibody has been diluted for use at 5 uL per test, defined as the amount of antibody that will stain a cell sample in a final volume of approximately 100 uL. The number of cells within a sample should be determined empirically, but typically ranges between 1x10e5 to 1x10e8 cells. |
| Storage Conditions | 2-8°C protected from light |
Jahnke M, Trowsdale J, and Kelly AP. 2012. J. Biol. Chem. 287: 28779-28789. (Flow Cytometry, Immunoprecipitation)
Clement M, Ladell K, Ekeruche-Makinde J, Miles JJ, Edwards ESJ, Dolton G, Williams T, Schauenburg AJA, Cole DK, Lauder SN, Gallimore AM, Godkin AJ, Burrows SR, Price DA, Sewell AK, and Wooldridge L. 2011. J. Immunol. 187: 654-663. (in vitro activation)
Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PEM, Simone R, Chum P, Yan X-Y, Allen SL, Kolitz JE, Baskar S, Radar C, Mellstedt H, Rabbani H, Lee A, Gregersen PK, Rai KR, and Chiorazzi N. 2011. Blood. 117: 5463-5472. (in vivo activation)
Teles RMB, Krutzik SR, Ochoa MT, Oliveira RB, Sarno EN, and Modlin RL. 2010. 78: 4634-4643. (Immunohistochemistry – OCT embedded frozen tissue)
Lai AY, Fatemi M, Dhasarathy A, Malone C, Sobol SE, Geigerman C, Jaye DL, Mav D, Shah R, Li L, and Wade PA. 2010. J. Exp. Med. 207: 1939-1950. (in vitro T cell depletion)
Thakral D, Dobbins J, Devine L, and Kavathas PB. 2008. J. Immunol. 180:7431-7442. (Immunoprecipitation)
Varghese JC and Kane KP. 2008. J. Immunol. 181: 6002-6009. (in vitro blocking)
Provided below are standard protocols that you may find useful for product applications.
Background
The OKT8 antibody is specific for the 32-34 kDa alpha chain of human CD8, known as CD8a or CD8 alpha. CD8a can form a homodimer (CD8 alpha-alpha), but is more commonly expressed as a heterodimer with a second chain known as CD8b or CD8 beta. CD8 acts as a co-receptor for antigen recognition and subsequent T cell activation that is initiated upon binding of the T cell receptor (TCR) to antigen-bearing MHC Class I molecules. The cytoplasmic domains of CD8 provide binding sites for the tyrosine kinase lck, facilitating intracellular signaling events that lead to T cell activation, development, and cytotoxic effector functions. CD8+ cytotoxic T cells (CTLs) play an important role in inducing cell death of tumor cells, as well as cells infected by virus, bacteria or parasites.
The OKT8 antibody is widely used as a phenotypic marker for CD8 on cytotoxic T cells, thymocytes, as well as on certain cell types that do not also express the TCR, including some NK cells and lymphoid dendritic cells. If used together with alternative antibodies Anti-Human CD8a clone RPA-T8 or Anti-Human CD8a clone Hit8a, the OKT8 antibody will not block binding of RPA-T8 or Hit8a.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
